Pembroke Management LTD Trims Position in Cellebrite DI Ltd. $CLBT

Pembroke Management LTD decreased its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 21.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,426,496 shares of the company’s stock after selling 393,132 shares during the quarter. Cellebrite DI comprises approximately 2.8% of Pembroke Management LTD’s portfolio, making the stock its 16th biggest position. Pembroke Management LTD owned 0.60% of Cellebrite DI worth $22,824,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Fox Run Management L.L.C. lifted its position in shares of Cellebrite DI by 3.9% in the 2nd quarter. Fox Run Management L.L.C. now owns 30,359 shares of the company’s stock worth $486,000 after purchasing an additional 1,127 shares during the period. Axim Planning & Wealth bought a new position in Cellebrite DI in the second quarter worth about $173,000. Bank of New York Mellon Corp lifted its holdings in Cellebrite DI by 11.6% in the second quarter. Bank of New York Mellon Corp now owns 1,287,954 shares of the company’s stock worth $20,607,000 after buying an additional 133,651 shares during the period. Sigma Planning Corp boosted its position in Cellebrite DI by 100.0% during the 2nd quarter. Sigma Planning Corp now owns 24,000 shares of the company’s stock valued at $384,000 after acquiring an additional 12,000 shares in the last quarter. Finally, Redmond Asset Management LLC grew its holdings in shares of Cellebrite DI by 65.9% during the 2nd quarter. Redmond Asset Management LLC now owns 189,637 shares of the company’s stock worth $3,034,000 after acquiring an additional 75,320 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on CLBT shares. JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $20.00 to $23.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Wall Street Zen lowered shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday. Lake Street Capital dropped their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, August 15th. Needham & Company LLC decreased their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, August 14th. Finally, Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cellebrite DI presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Cellebrite DI Trading Up 1.4%

CLBT stock opened at $15.61 on Tuesday. The stock’s 50 day simple moving average is $17.74 and its 200 day simple moving average is $16.72. Cellebrite DI Ltd. has a 12-month low of $13.10 and a 12-month high of $26.30. The stock has a market capitalization of $3.74 billion, a PE ratio of -20.54, a price-to-earnings-growth ratio of 3.16 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The firm had revenue of $113.28 million during the quarter, compared to analysts’ expectations of $112.33 million. During the same quarter in the previous year, the business earned $0.10 earnings per share. The company’s revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.